Cancer remains one of the leading causes of morbidity and mortality worldwide, necessitating the development of advanced therapeutic strategies with improved efficacy and reduced toxicity. Conventional cancer treatments are often limited by poor drug solubility, non-specific distribution, systemic side effects, and the development of drug resistance. Targeted drug delivery systems, particularly nanotechnology-based approaches, have emerged as promising solutions to overcome these challenges. Solid Lipid Nanoparticles (SLNs) are biocompatible and biodegradable carriers capable of enhancing drug stability, bioavailability, controlled release, and targeted delivery. Nilotinib, a second-generation BCR-ABL tyrosine kinase inhibitor, is widely used in the treatment of chronic myeloid leukemia; however, its clinical application is constrained by limited bioavailability and adverse effects. Rutin, a natural bioflavonoid, exhibits potent antioxidant, anti-inflammatory, anti-angiogenic, and pro-apoptotic properties, making it a valuable adjunct in cancer therapy. The co-encapsulation of Nilotinib and Rutin into SLNs offers a synergistic therapeutic approach by enhancing solubility, improving cellular uptake, reducing systemic toxicity, and overcoming multidrug resistance. This project focuses on the formulation and application of Nilotinib and Rutin-loaded SLNs as an innovative strategy for enhanced cancer treatment. The SLN-based delivery system holds significant potential for improving therapeutic outcomes and advancing personalized cancer therapy.